VT H0859

Creates a Psychedelic Therapy Advisory Board with 11 members including health care professionals, mental health experts, and individuals with lived experience to review research on psychedelic therapy for mental health and substance use disorders, with a report due January 15, 2027 and the board dissolving July 1, 2027.

Requires the Department of Health to contract with a Vermont entity to conduct FDA-sanctioned ibogaine clinical drug development trials for treating opioid use disorder, substance use disorders, traumatic brain injury, and other mental health conditions.

Appropriates $300,000 from the Opioid Abatement Special Fund to fund the ibogaine clinical trials, with the contracted entity required to match state funding and use Vermont facilities and residents as trial participants.

Establishes an Ibogaine Intellectual Property Special Fund to collect proceeds from commercialized research, with funds restricted to programs benefiting populations with conditions treatable by ibogaine.

Provides civil and criminal liability immunity for health care professionals prescribing or dispensing ibogaine as part of authorized clinical trials, unless their actions constitute recklessness, gross negligence, or intentional misconduct.